Erratum: Tetra-substituted pyridinylimidazoles as dual inhibitors of p38α mitogen-activated protein Kinase and c-Jun N-terminal Kinase 3 for potential treatment of neurodegenerative diseases (Journal of Medicinal Chemistry (2015) 58 (443-456) DOI:10.1021/jm501557a);Tetra-substituted pyridinylimidazoles as dual inhibitors of p38α mitogen-activated protein kinase and c-jun N-terminal kinase 3 for potential treatment of neurodegenerative diseases

Journal of Medicinal Chemistry

Volumn 58, Issue 1, 2015, Pages 443-456

  Muth, Felix ^a   Günther, Marcel ^a   Bauer, Silke M ^a   Döring, Eva ^a   Fischer, Sabine ^a   Maier, Julia ^a   Drückes, Peter ^b   Köppler, Jürgen ^b   Trappe, Jörg ^b   Rothbauer, Ulrich ^a   Koch, Pierre ^a   Laufer, Stefan A ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

3 [5 (2 (SEC BUTYLAMINO)PYRIDIN 4 YL) 1 (2,2 DIMETHOXYETHYL) 4 (4 FLUOROPHENYL) 1H IMIDAZOL2 YL)THIO]ACRYLIC ACID; ENZYME INHIBITOR; IMIDAZOLE DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE 10; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; UNCLASSIFIED DRUG; MITOGEN ACTIVATED PROTEIN KINASE 14; MOLECULAR LIBRARY; PROTEIN BINDING; PROTEIN KINASE INHIBITOR; PYRIDINE DERIVATIVE;

ARTICLE; DEGENERATIVE DISEASE; DISEASE COURSE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IC50; METABOLIC STABILITY; SUBSTITUTION REACTION; ANTAGONISTS AND INHIBITORS; CELL SURVIVAL; CHEMICAL MODEL; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; DRUG DESIGN; DRUG EFFECTS; HUNTINGTON DISEASE; LIVER MICROSOME; MALE; METABOLISM; MOLECULAR LIBRARY; NEURODEGENERATIVE DISEASES; PHARMACOLOGY; PROTEIN TERTIARY STRUCTURE; TUMOR CELL LINE;

CELL LINE, TUMOR; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; HUMANS; HUNTINGTON DISEASE; IMIDAZOLES; MALE; MICROSOMES, LIVER; MITOGEN-ACTIVATED PROTEIN KINASE 10; MITOGEN-ACTIVATED PROTEIN KINASE 14; MODELS, CHEMICAL; MODELS, MOLECULAR; MOLECULAR STRUCTURE; NEURODEGENERATIVE DISEASES; PROTEIN BINDING; PROTEIN KINASE INHIBITORS; PROTEIN STRUCTURE, TERTIARY; PYRIDINES; SMALL MOLECULE LIBRARIES;

EID: 84928429443     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.5b00235     Document Type: Erratum

References (27)

1. Chang, L. F.; Karin, M. Mammalian MAP kinase signalling cascades Nature 2001, 410 (6824) 37-40
2. Davis, R. J. Signal transduction by the JNK group of MAP kinases Cell 2000, 103 (2) 239-252
3. Han, J.; Ulevitch, R. J. Emerging targets for anti-inflammatory therapy Nature Cell Biol. 1999, 1 (2) E39-E40
4. Schaeffer, H. J.; Weber, M. J. Mitogen-activated protein kinases: specific messages from ubiquitous messengers Mol. Cell. Biol. 1999, 19 (4) 2435-2444
5. Bogoyevitch, M. A.; Kobe, B. Uses for JNK: The Many and Varied Substrates of the c-Jun N-Terminal Kinases Microbiol. Mol. Biol. Rev. 2006, 70 (4) 1061-1095
6. Seki, E.; Brenner, D. A.; Karin, M. A Liver Full of JNK: Signaling in Regulation of Cell Function and Disease Pathogenesis, and Clinical Approaches Gastroenterology 2012, 143 (2) 307-320
7. Wagner, E. F.; Nebreda, A. R. Signal integration by JNK and p38 MAPK pathways in cancer development Nature Rev. Cancer 2009, 9 (8) 537-549
8. Walker, F. O. Huntington's disease Lancet 2007, 369 (9557) 218-228
9. Biglan, K. M.; Ross, C. A.; Langbehn, D. R.; Aylward, E. H.; Stout, J. C.; Queller, S.; Carlozzi, N. E.; Duff, K.; Beglinger, L. J.; Paulsen, J. S.; Group, H. S. Motor Abnormalities in Premanifest Persons with Huntington's Disease: The PREDICT-HD Study Movement Disord. 2009, 24 (12) 1763-1772
10. Duff, K.; Paulsen, J. S.; Beglinger, L. J.; Langbehn, D. R.; Wang, C.; Stout, J. C.; Ross, C. A.; Aylward, E.; Carlozzi, N. E.; Queller, S. "Frontal" behaviors before the diagnosis of Huntington's disease and its relationship to markers of disease progression: evidence of early lack of awareness J. Neuropsychiatry Clin. Neurosci. 2010, 22 (2) 196-207
11. Bürli, R. W.; Luckhurst, C. A.; Aziz, O.; Matthews, K. L.; Yates, D.; Lyons, K. A.; Beconi, M.; McAllister, G.; Breccia, P.; Stott, A. J.; Penrose, S. D.; Wall, M.; Lamers, M.; Leonard, P.; Müller, I.; Richardson, C. M.; Jarvis, R.; Stones, L.; Hughes, S.; Wishart, G.; Haughan, A. F.; O'Connell, C.; Mead, T.; McNeil, H.; Vann, J.; Mangette, J.; Maillard, M.; Beaumont, V.; Munoz-Sanjuan, I.; Dominguez, C. Design, Synthesis, and Biological Evaluation of Potent and Selective Class IIa Histone Deacetylase (HDAC) Inhibitors as a Potential Therapy for Huntington's Disease J. Med. Chem. 2013, 56 (24) 9934-9954
12. Ehrnhoefer, D. E.; Wong, B. K. Y.; Hayden, M. R. Convergent pathogenic pathways in Alzheimer's and Huntington disease: Shared targets for drug development Nature Rev. Drug Discovery 2011, 10 (11) 853-867
13. Túnez, I.; Sánchez-López, F.; Agüera, E.; Fernández-Bolaños, R.; Sánchez, F. M.; Tasset-Cuevas, I. Important Role of Oxidative Stress Biomarkers in Huntington's Disease J. Med. Chem. 2011, 54 (15) 5602-5606
14. Taylor, D. M.; Moser, R.; Regulier, E.; Breuillaud, L.; Dixon, M.; Beesen, A. A.; Elliston, L.; Santos, M. D. S.; Kim, J.; Jones, L.; Goldstein, D. R.; Ferrante, R. J.; Luthi-Carter, R. MAP Kinase Phosphatase 1 (MKP-1/DUSP1) Is Neuroprotective in Huntington's Disease via Additive Effects of JNK and p38 Inhibition J. Neurosci. 2013, 33 (6) 2313-2325
15. Knapp, S.; Arruda, P.; Blagg, J.; Burley, S.; Drewry, D. H.; Edwards, A.; Fabbro, D.; Gillespie, P.; Gray, N. S.; Kuster, B.; Lackey, K. E.; Mazzafera, P.; Tomkinson, N. C. O.; Willson, T. M.; Workman, P.; Zuercher, W. J. A public-private partnership to unlock the untargeted kinome Nature Chem. Biol. 2013, 9 (1) 3-7
16. Laufer, S.; Hauser, D.; Stegmiller, T.; Bracht, C.; Ruff, K.; Schattel, V.; Albrecht, W.; Koch, P. Tri- and tetrasubstituted imidazoles as p38 alpha mitogen-activated protein kinase inhibitors Bioorg. Med. Chem. Lett. 2010, 20 (22) 6671-6675
17. Laufer, S. A.; Wagner, G. K.; Kotschenreuther, D. A.; Albrecht, W. Novel substituted pyridinyl imidazoles as potent anticytokine agents with low activity against hepatic cytochrome P450 enzymes J. Med. Chem. 2003, 46 (15) 3230-3244
18. Laufer, S. A.; Zimmermann, W.; Ruff, K. J. Tetrasubstituted imidazole inhibitors of cytokine release: probing substituents in the N-1 position J. Med. Chem. 2004, 47 (25) 6311-6325
19. Ziegler, K.; Hauser, D. R. J.; Unger, A.; Albrecht, W.; Laufer, S. A. 2-Acylaminopyridin-4-ylimidazoles as p38 MAP Kinase Inhibitors: Design, Synthesis, and Biological and Metabolic Evaluations ChemMedChem 2009, 4 (11) 1939-1948
20. Abu Thaher, B.; Koch, P.; Schattel, V.; Laufer, S. Role of the Hydrogen Bonding Heteroatom-Lys53 Interaction between the p38 alpha Mitogen-Activated Protein (MAP) Kinase and Pyridinyl-Substituted 5-Membered Heterocyclic Ring Inhibitors J. Med. Chem. 2009, 52 (8) 2613-2617
21. Goettert, M.; Graeser, R.; Laufer, S. A. Optimization of a nonradioactive immunosorbent assay for p38 alpha mitogen-activated protein kinase activity Anal. Biochem. 2010, 406 (2) 233-234
22. Goettert, M.; Luik, S.; Graeser, R.; Laufer, S. A. A direct ELISA assay for quantitative determination of the inhibitory potency of small molecules inhibitors for JNK3 J. Pharm. Biomed. Anal. 2011, 55 (1) 236-240
23. Koch, P.; Gehringer, M.; Laufer, S. A., Inhibitors of cJun-N-terminal kinases (update). J. Med. Chem., DOI: 10.1021/jm501212r.
24. Wagner, G. K.; Kotschenreuther, D.; Zimmermann, W.; Laufer, S. A. Identification of regioisomers in a series of N-substituted pyridin-4-yl imidazole derivatives by regiospecific synthesis, GC/MS, and H-1 NMR J. Org. Chem. 2003, 68 (11) 4527-4530
25. Beruben, D.; Marek, I.; Normant, J. F.; Platzer, N. Stereodefined Substituted Cyclopropyl Zinc Reagents from Gem-Bismetallics J. Org. Chem. 1995, 60 (8) 2488-2501
26. Takeuchi, R.; Tanabe, K.; Tanaka, S. Stereodivergent synthesis of (E)- and (Z)-2-alken-4-yn-1-ols from 8-propynoic acid: a practical route via 2-alken-4-ynoates (Vol. 65, p 1558, 2000) J. Org. Chem. 2000, 65 (11) 3570-3570
27. Kao, H. L.; Chen, C. K.; Wang, Y. J.; Lee, C. F. An Efficient Copper-Catalyzed Cross-Coupling Reaction of Thiols with Aryl Iodides Eur. J. Org. Chem. 2011, 9, 1776-1781